MannKind | Eiendeler



Assets Endring Dato
Adma Biologics USD 488.68M 98.06M 2024-12
Dynavax Technologies USD 986.26M 75.73M 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Halozyme Therapeutics USD 2.06B 54.55M 2024-12
Insmed USD 2.03B 27.74M 2024-12
MacroGenics USD 264.49M 63.36M 2024-09
MannKind USD 393.84M 70.36M 2024-12
Merck USD 117.11B 426M 2024-12
Novo Nordisk DKK 397.44B 28.06B 2024-09
Pfizer USD 213.4B 6.08B 2024-12
Sanofi 129.76B 3.29B 2024-06
Xencor USD 951.94M 31.69M 2024-12



MannKind Eiendeler - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.